Antibodies and antibody-derived macromolecules have established themselves as the
mainstay in protein-based therapeutic molecules (biologics). Our knowledge of the structure …

Alzheimer disease (AD) is the most common cause of dementia in older individuals. AD is
characterized pathologically by amyloid-β (Aβ) plaques and tau neurofibrillary tangles in the …

Abstract As of May 1, 2017, 74 antibody-based molecules have been approved by a
regulatory authority in a major market. Additionally, there are 70 and 575 antibody-based …

There are many factors that can influence the pharmacokinetics (PK) of a mAb or Fc-fusion
molecule with the primary determinant being FcRn-mediated recycling. Through Fab or Fc …

Summary Background Avelumab (MSB0010718C) is a human IgG1 monoclonal antibody
that binds to PD-L1, inhibiting its binding to PD-1, which inactivates T cells. We aimed to …

Despite the therapeutic success of monoclonal antibodies (mAbs), early identification of
developable mAb drug candidates with optimal manufacturability, stability, and delivery …

Feeding biopharma pipelines with biotherapeutic candidates that possess desirable
developability profiles can help improve the productivity of biologic drug discovery and …

Highlights•Therapeutic Abs come from critical screenings of in vivo and in vitro
methods.•Bispecific Abs increase specificity and broaden the range of therapeutic …

Large-molecule antibody biologics have revolutionized medicine owing to their superior
target specificity, pharmacokinetic and pharmacodynamic properties, safety and toxicity …

abstract Protein therapeutics represent a diverse array of biologics including antibodies,
fusion proteins, and therapeutic replacement enzymes. Since their inception, they have …